Friday, Sep 5, 2025
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Olympics
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Business | Dr Reddys Signs Agreement With Takeda Pharma To Market Vonoprazan Tabs In India

Dr. Reddy’s signs agreement with Takeda Pharma, to market Vonoprazan tabs in India

Dr. Reddy’s will market Vonoprazan tablets under its own trademark VONOTM to be available in two strengths of 10mg and 20mg.

By Telangana Today
Updated On - 19 July 2024, 01:06 PM
Dr. Reddy’s signs agreement with Takeda Pharma, to market Vonoprazan tabs in India
whatsapp facebook twitter telegram

Hyderabad: Dr. Reddy’s Laboratories Limited has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.

Dr. Reddy’s will market Vonoprazan tablets under its own trademark VONOTM to be available in two strengths of 10mg and 20mg.

Also Read

  • Dr. Reddy’s Labs SA signs agreement with Haleonplc for purchase of Northstar Switzerland SARL shares

Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), are very common in India. A pan-Indian cross-sectional survey of clinicians showed APD

prevalence to be in the range of 37percent to 39 per cent. It is more common in the 18-59 age group, with heartburn and epigastric pain as common symptoms, a press release from the company said.

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, in the press release said, “For over three decades, patients and healthcare professionals have trusted our products in the gastrointestinal

segment including well-known brands such as Omez, RazoTM and others. Leveraging our expertise in this therapy area, we are pleased to make the first-in-class drug Vonoprazan (VonoTM) available to patients in India”

  • Follow Us :
  • Tags
  • Dr. Reddy’s
  • Takeda Pharma
  • Vonoprazan tablets

Related News

  • Dr Reddy’s launch anti-cancer drug for aggressive head and neck cancer

    Dr Reddy’s launch anti-cancer drug for aggressive head and neck cancer

  • Dr. Reddy’s announces licensing agreement with Takeda Pharmaceutical to commercialise Vonoprazan tablets in India

    Dr. Reddy’s announces licensing agreement with Takeda Pharmaceutical to commercialise Vonoprazan tablets in India

  • Dr. Reddy’s Labs SA signs agreement with Haleonplc for purchase of Northstar Switzerland SARL shares

    Dr. Reddy’s Labs SA signs agreement with Haleonplc for purchase of Northstar Switzerland SARL shares

  • UoH, Dr Reddy’s win patent for psoriasis treatment mode

    UoH, Dr Reddy’s win patent for psoriasis treatment mode

Latest News

  • Hyderabad Pickleball League: Saina joins Keerthi Warriors as co-owner

    4 hours ago
  • Hyderabad sports roundup: Snehit, Sreeja for Asian Table Tennis

    4 hours ago
  • Doubles shuttler Jwala Gutta distributes kit to Telangana fencing squad members

    5 hours ago
  • Mahadev crushes Mayura as Preethesh hits unbeaten 148 in HCA C-Division championship

    5 hours ago
  • Yuvraj launches innovative multi-city Indian Golf Premier League

    5 hours ago
  • The Gambits, a documentary on Global Chess League

    5 hours ago
  • Traffic curbs in Hyderabad for Ganesh idol immersion on Saturday

    5 hours ago
  • 10 indian boxers get bye in first round of World Boxing Championships

    5 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam